KARYOPHARM THERAPEUTICS INC (KPTI)
US48576U1060 - Common Stock
Taking everything into account, KPTI scores 2 out of 10 in our fundamental rating. KPTI was compared to 564 industry peers in the Biotechnology industry. KPTI has a bad profitability rating. Also its financial health evaluation is rather negative. KPTI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KPTI had negative earnings in the past year.
In the past year KPTI has reported a negative cash flow from operations.
KPTI had negative earnings in each of the past 5 years.
In the past 5 years KPTI always reported negative operating cash flow.
1.2 Ratios
KPTI has a Return On Assets (-42.02%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.02% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-48.77%
ROA(5y)-55.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 96.04%, KPTI belongs to the top of the industry, outperforming 96.26% of the companies in the same industry.
In the last couple of years the Gross Margin of KPTI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for KPTI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.3%
GM growth 5YN/A
2. Health
2.1 Basic Checks
KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KPTI has been increased compared to 1 year ago.
KPTI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KPTI is higher compared to a year ago.
2.2 Solvency
KPTI has an Altman-Z score of -10.12. This is a bad value and indicates that KPTI is not financially healthy and even has some risk of bankruptcy.
KPTI's Altman-Z score of -10.12 is on the low side compared to the rest of the industry. KPTI is outperformed by 77.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.12 |
ROIC/WACCN/A
WACC5.31%
2.3 Liquidity
KPTI has a Current Ratio of 3.62. This indicates that KPTI is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.62, KPTI perfoms like the industry average, outperforming 40.82% of the companies in the same industry.
KPTI has a Quick Ratio of 3.56. This indicates that KPTI is financially healthy and has no problem in meeting its short term obligations.
KPTI has a Quick ratio (3.56) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.56 |
3. Growth
3.1 Past
KPTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.54%, which is quite impressive.
KPTI shows a decrease in Revenue. In the last year, the revenue decreased by -0.23%.
The Revenue has been growing by 36.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.72%
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y10.55%
Revenue growth 5Y36.96%
Sales Q2Q%13.86%
3.2 Future
Based on estimates for the next years, KPTI will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.24% on average per year.
Based on estimates for the next years, KPTI will show a very strong growth in Revenue. The Revenue will grow by 21.97% on average per year.
EPS Next Y46.01%
EPS Next 2Y20.49%
EPS Next 3Y18.31%
EPS Next 5Y15.24%
Revenue Next Year3.15%
Revenue Next 2Y7.41%
Revenue Next 3Y11.36%
Revenue Next 5Y21.97%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KPTI. In the last year negative earnings were reported.
Also next year KPTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KPTI's earnings are expected to grow with 18.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.49%
EPS Next 3Y18.31%
5. Dividend
5.1 Amount
No dividends for KPTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KARYOPHARM THERAPEUTICS INC
NASDAQ:KPTI (11/1/2024, 8:12:40 PM)
Premarket: 0.97 +0.07 (+7.4%)0.9032
-0.09 (-8.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap112.61M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.02% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.62 | ||
| Quick Ratio | 3.56 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)43.54%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y46.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.23%
Revenue growth 3Y10.55%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y